Table 1.
Top Canonical Pathways | p-value | Overlap | Ratio |
Tryptophan Degradation (Eukaryotic) | 1.15E-12 | 42.9% | 9/21 |
Super-pathway of Cholesterol Biosynthesis | 9.65E-10 | 28.6% | 8/28 |
Cholesterol Biosynthesis I-III | 4.48E-09 | 46.2% | 6/13 |
NAD Biosynthesis II | 9.23E-09 | 40.0% | 6/15 |
Tryptophan Degradation 2-amino-3-carboxymuconate | 9.83E-09 | 62.5% | 5/8 |
Top Upstream Regulators | p-value of overlap | # Target genes | |
SREBF2 | 1.08E-15 | 19 | |
PPARA | 9.38E-14 | 27 | |
SREBF1 | 2.55E-13 | 15 | |
PPARG | 3.15E-09 | 24 | |
PPARGC1A | 1.07E-08 | 18 | |
Top Molecular and Cellular Functions | p-value | # Genes | |
Amino Acid Metabolism | 9.80E-03 - 6.26E-11 | 25 | |
Small Molecule Biochemistry | 1.19–02 - 6.26E-11 | 94 | |
Lipid Metabolism | 1.19–02 - 2.16E-08 | 66 | |
Molecular Transport | 1.19–02 - 2.16E-08 | 68 | |
Vitamin and Mineral Metabolism | 5.45E-03 - 7.14E-07 | 21 | |
Physiological System Development and Function | p-value | # Genes | |
Connective Tissue Development and Function | 1.13E-02 - 3.88E-04 | 26 | |
Digestive System Development and Function | 1.02E-02 - 4.29E-04 | 17 | |
Hepatic System Development and Function | 6.03E-03 - 4.29E-04 | 17 | |
Organ Morphology | 1.13E-02 - 4.29E-04 | 21 | |
Organismal Development | 1.13E-02 - 4.29E-04 | 19 | |
Top Up-regulated genes | D1FED24h/D1FAST24h | Top Down-regulated genes | D1FED24h/D1FAST24h |
THRSPA | 4.46 | UPP2 | −2.70 |
DIO2 | 3.24 | CYP4A22 | −2.01 |
HKDC1 | 3.22 | HMGCS1 | −1.89 |
ME1 | 2.75 | CYP3A7 | −1.73 |
PLIN2 | 2.63 | TDH | −1.62 |
FADS2 | 2.47 | FKBP5 | −1.62 |
MSMO1 | 2.21 | ADSL | −1.60 |
CYP51A1 | 2.06 | ECI2 | −1.52 |
SCD | 1.74 | CYP2C44 | −1.44 |
BATF3 | 1.72 | LDHB | −1.37 |
Ingenuity Pathway Analysis (IPA) was used for functional analysis of 259 DEGs (FDR adj. P ≤ 0.05) that were also “Analysis Ready” (AR)-DEGs from the D1FED24h vs. D1FAST24h contrast. The top 10 up-regulated and down-regulated AR-DEGs are presented along with their respective log2 ratio of treatment conditions